The landmark cardiovascular outcomes trialsincluding SUSTAIN-6 for semaglutide and LEADER for liraglutidespecifically evaluated cardiovascular safety endpoints and did not report increased rates of venous thromboembolism compared to placebo, though it's important to note that VTE was not a primary endpoint in these studies
Autoimmune gastritis is often thought of as the dominant reason for atrophic gastritis
Patients commonly see redness at the treatment site immediately following treatment which fades within 1-2 days, and are recommended to protect their treated areas from sun exposure for at least 2 weeks following treatment
Wang W, Lin W, Hong B, Li X, Zhang M, Zhang L, et al
Key Benefits Potassium supports normal nervous system function
Pevec et al., 2010) and worsening, as well as immunosuppression (Sikiric et al., 2003)